ReviewRecent patents on anti-infective drug discovery2012
Current and emerging antivirals for the treatment of cytomegalovirus (CMV) retinitis: an update on recent patents.
Review in Recent patents on anti-infective drug discovery, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 39 citations in OpenAlex.
- Eye on cytomegalovirus: Unveiling the ophthalmic impact of cytomegalovirus.World journal of virology · 2025Article
- Article
- Diagnostic and therapeutic challenges in acute retinal necrosis; an update.Eye (London, England) · 2024Review
- Viruses in glioblastoma: an update on evidence and clinical trials.BJC reports · 2024Review
- Article
- Cytomegalovirus retinitis in the highly active anti-retroviral therapy era.Annals of eye science · 2022Article
- Pre-Transplant Platelet Refractoriness and Alternative Donors Are Associated With Cytomegalovirus Retinitis in Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia.Frontiers in cellular and infection microbiology · 2022Article
- Cytomegalovirus-Specific T Cells from Third-Party Donors Successfully Treated Refractory Cytomegalovirus Retinitis after Unrelated Umbilical Cord Blood Transplantation.Journal of immunology research · 2022Article
- Use of Letermovir for Salvage Therapy for Resistant Cytomegalovirus in a Pediatric Hematopoietic Stem Cell Transplant Recipient.Journal of the Pediatric Infectious Diseases Society · 2020Article
- Cytomegalovirus Retinitis in HIV and Non-HIV Individuals.Microorganisms · 2019Review
- SOCS and Herpesviruses, With Emphasis on Cytomegalovirus Retinitis.Frontiers in immunology · 2019Review
- Nanotechnology in retinal drug delivery.International journal of ophthalmology · 2018Review
- Article
- Treatment of cytomegalovirus retinitis with cytomegalovirus-specific T-lymphocyte infusion.Ophthalmic surgery, lasers & imaging retina · 2015Article
- Decrease of murine cytomegalovirus-induced retinitis by intravenous delivery of immediate early protein-3-specific siRNA.Investigative ophthalmology & visual science · 2014Article
- Update on emerging antivirals for the management of herpes simplex virus infections: a patenting perspective.Recent patents on anti-infective drug discovery · 2013Review
- Novel strategies for anterior segment ocular drug delivery.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics · 2013Review
- Nanomicelles: an emerging platform for drug delivery to the eye.Therapeutic delivery · 2013Article
- Sodium dependent multivitamin transporter (SMVT): a potential target for drug delivery.Current drug targets · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Cytomegalovirus (CMV) retinitis is the most common ocular opportunistic complication and a serious cause of vision loss in immunocompromised patients. Even though, a rise in human immunodeficiency virus (HIV) infected individuals seems to be a major factor responsible for the prevalence of CMV retinitis, the introduction of highly active antiretroviral therapy (HAART) significantly reduced the incidence and severity of CMV retinitis. Thorough evaluation of the patient's immune status and an exact classification of the retinal lesions may provide better understanding of the disease etiology, which would be necessary for optimizing the treatment conditions. Current drugs such as ganciclovir, valganciclovir, cidofovir and foscarnet have been highly active against CMV, but prolonged therapy with these approved drugs is associated with dose-limiting toxicities thus limiting their utility. Moreover development of drug-resistant mutants has been observed particularly in patients with acquired immunodeficiency syndrome (AIDS). Continuous efforts by researchers in the industry and academia have led to the development of newer candidates with enhanced antiviral efficacy and apparently minimal side effects. These novel compounds can suppress viral replication and prevent reactivation in the target population. Though some of the novel therapeutics possess potent viral inhibitory activity, these compounds are still in stages of clinical development and yet to be approved. This review provides an overview of disease etiology, existing anti-CMV drugs, advances in emerging therapeutics in clinical development and related recent patents for the treatment of CMV retinitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.